About: rare diseases

Special ReportPromoted content
Health 24-07-2020

Europe at the crossroad of Rare Diseases innovation: lessons from the past and future outlooks

In shaping the future of rare diseases policies all stakeholders should cooperate to create an environment that actively supports research and clinical development of orphan medicinal products (OMPs). This entails building synergies all across the innovation ecosystem to address the...
Special ReportPromoted content
Health 13-07-2020

The complexity of R&D for orphan medicines

There are multiple challenges inherent to drug development for rare diseases, all consequences of the small number of patients. For most of these diseases, the body of pre-existing knowledge is extremely limited with a lack of crucial information such as...
Special ReportPromoted content
Health 10-07-2020

From pandemic to rare disease, medical innovation is the answer

Living through a global pandemic, we can take some comfort from the enormous collaborative research and development response that is taking place to find a way out from under the shadow of the COVID-19 crisis. Scientists around the world are...
Health 13-02-2017

Commission must bring healthcare to the fore

Given that the current European Commission has not prioritised healthcare, it looks as though it is up to the European Parliament to push the agenda, writes Denis Horgan.
Health 13-02-2017

Health matters should supersede European bureaucracy

European red tape should not be an obstacle to effective healthcare. For patients with diseases like sarcoma, waiting means suffering and often avoidable death, writes Marlene Mizzi.
Development Policy 22-10-2015

Ivermectin: A Nobel Prize medicine inaccessible to the world’s poorest

The true potential of new medical breakthroughs can only be unlocked if they are offered at an affordable cost to those who need them most, writes Jose Muñoz.

A breakthrough in combating rare genetic disorders

Europe can lead the way in developing gene therapies to tackle the growing and persistent problem of previously incurable diseases, with huge potential benefits for both patients and industry. Europe needs to promote cross-border research and facilitate access to these new therapies, argues Aurelio Maggio.
Contribute